Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours Β· Estimated delivery Sep 5 - Sep 10
* Definition: The incretin mimetics market consists of pharmaceutical therapies that mimic the effects of incretin hormones like glucagon-like peptide-1 (GLP-1)
Most members pay less than $30/visit
Authorize Dark Mode Reduce eye strain and focus on the content that matters
:max_bytes(150000):strip_icc()/Simple-7-Day-GLP-1-Friendly-Meal-Plan-for-Beginners-Created-by-a-Dietitian-69f3d02b6c2c41928135df7f0c417552.jpg)
Consequently, companies such as Novo Nordisk and Eli Lilly are investing heavily in next-generation formulations, including oral small-molecule GLP-1 receptor agonists such as orforglipron, which aim to expand patient accessibility and therapeutic scope The demand for GLP-1 drugs that address a wider array of metabolic conditions is growing rapidly across global markets, as patients and healthcare providers increasingly seek holistic and effective long-term treatment options for obesity and its comorbidities GLP-1 Receptor Agonists Obesity Drugs Market Dynamics Driver Surging Demand Due to Rising Obesity Prevalence and Enhanced Clinical Outcomes The global surge in obesity rates and associated comorbidities such as type 2 diabetes and cardiovascular diseases is significantly driving demand for GLP-1 receptor agonist drugs as effective medical weight loss therapies For instance, in May 2024, Novo Nordisk announced a USD 4.1 billion expansion in its U.S
US$ 21.34
US$ 26.83
US$ 20.74
